Unlock instant, AI-driven research and patent intelligence for your innovation.

Furo-pyridone amide compound as well as preparation method and application thereof

A compound, benzo-based technology, applied in the field of coagulation factor XIa inhibitors, can solve problems such as unsatisfactory

Pending Publication Date: 2021-07-20
JIANGXI JEMINCARE GRP CO LTD +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Plasma kininase inhibitor The macromolecular protein drug Ecallantide (Kalbitor) has been approved by the FDA for the treatment of HAE. However, no small molecule plasma kininase inhibitor has been approved for marketing so far. The development of a safe and effective small molecule inhibitor of Kallikrein may also meet the requirements. clinical unmet need

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Furo-pyridone amide compound as well as preparation method and application thereof
  • Furo-pyridone amide compound as well as preparation method and application thereof
  • Furo-pyridone amide compound as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0096] Embodiment 1: the synthesis of compound A1

[0097]

[0098] Step 1. Preparation of Intermediate 1

[0099] 2-Bromo-4-chloro-nitrobenzene (4729 mg, 20.00 mmol), pinacol diboronate (6095 mg, 24.00 mmol), KOAc (3926 mg, 40.00 mmol) were added to 1,4-dioxane ( 40mL). Pd(dppf)Cl 2 (1463 mg, 2.00 mmol) was added to the above mixture. Reaction system uses N 2 Under protection, the temperature was raised to 100°C, and the reaction was carried out overnight. The reaction solution was spin-dried and purified by column chromatography (biotage, 80 g, silica gel column, UV254, DCM / PE=0-50%) to obtain Intermediate 1. 1 HNMR (400MHz, DMSO-d 6 )δ8.21(d, J=8.8Hz, 1H), 7.78(dd, J=8.8, 2.4Hz, 1H), 7.71(d, J=2.3Hz, 1H), 1.35(s, 12H).

[0100] Step 2. Preparation of Intermediate 3

[0101] Compound 2 (methyl 3-aminofuran-2-carboxylate, 850mg, 6.02mmol) was dissolved in 10mL of MeOH, p-methoxybenzaldehyde (984mg, 7.20mmol) was added, and acetic acid (361mg , 6.02mmol), sodium cyan...

Embodiment 2

[0122] Embodiment 2: the synthesis of compound A2

[0123]

[0124]

[0125] Step 1. Synthesis of Intermediate 15

[0126] Add compound 14 (2.5g, 12.1mmol) into the three-neck flask, replace the nitrogen, add 60mL of tetrahydrofuran, add dropwise oxalyl chloride (2.4ml, 27.9mmol) in ice bath, add 0.1mL of DMF, spin dry after 30min, and pump Dry. Replace nitrogen, redissolve in 30mL tetrahydrofuran, lower the temperature to minus 40°C, dissolve potassium tert-butoxide in 40mL tetrahydrofuran and add dropwise to the reaction system, transfer to room temperature for 30min after 10min, add ice water dropwise to quench , extracted with EA (200ml*3), combined the organic phases, dried and concentrated to obtain the crude intermediate 15. LC-MS: m / z 263.0 (M+H) + ; 1 H NMR (400MHz, Chloroform-d) δ9.18(s, 1H), 8.66(s, 1H), 8.21(d, J=11.3Hz, 1H), 7.51–7.43(m, 1H), 7.32–7.28( m,1H),1.63(s,9H).

[0127] Step 2. Synthesis of Intermediate 16

[0128] Intermediate 16 (2.0g, 7.6...

Embodiment 7

[0157] Embodiment 7: the synthesis of compound A7

[0158]

[0159] The synthetic route of its key intermediate is as follows:

[0160]

[0161] Step 1. Synthesis of Intermediate 28

[0162] In a 250mL three-neck round bottom flask, add 2,2,2-trifluoroethylamine hydrochloride (4050mg, 30.0mmol) and NaNO 2 (2277mg, 33mmol) under argon protection. Then, toluene (60 mL) degassed with argon was added, and the reaction solution was cooled to 0° C. in an ice bath, and stirred for 30 minutes. Additional water (6 mL) degassed with argon was added. After the addition, react at 0°C for 2 hours, then raise the temperature to 10°C, and react for another 30 minutes. After the reaction, the reaction solution was placed in a refrigerator (about -18° C.) for 16 hours. Then transfer the organic phase in the reaction solution to a dry 250mL round bottom flask, add anhydrous K 2 CO 3 (3000 mg), stirred and dried for 1 hour to obtain a dry toluene solution of intermediate 28, 60 mL, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicinal chemistry. The invention relates to a furo-pyridone amide compound as well as a preparation method and application thereof. Specifically, the structure of the compound is shown as a general formula (I) in the specification. The compounds or stereoisomers, racemes, geometric isomers, tautomers, prodrugs, hydrates, solvates or pharmaceutically acceptable salts and pharmaceutical compositions thereof can be used for treating or / and preventing related diseases mediated by an XIa factor (FXIa for short);.

Description

technical field [0001] The invention belongs to the field of medicinal chemistry. Specifically, the present invention relates to novel compounds or stereoisomers, racemates, geometric isomers, tautomers, prodrugs, hydrates, solvates or pharmaceutically acceptable salts thereof, and The pharmaceutical composition containing them is a blood coagulation factor XIa (Factor XIa, FXIa for short) inhibitor with a new structure. Background technique [0002] Thromboembolism is a disease of humans and animals caused by abnormal blood clots that form in blood vessels during their lifetime. There are three reasons for thrombosis: damaged blood vessels, blood changes and blood stasis; it is a group of complications caused by many different diseases and different reasons. Due to the differences in various underlying diseases and the different sites of thromboembolism, thrombosis may clinically manifest as myocardial infarction, stroke, deep vein thrombosis (deep vein thrombosis, DVT), ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D491/048C07D519/00A61K31/4355A61K31/438A61K31/437A61P7/02
CPCC07D491/048C07D519/00A61P7/02
Inventor 张琼姚虞财刘小斌桓锐李中尧罗九郭淑春叶艳彭建彪郭海兵
Owner JIANGXI JEMINCARE GRP CO LTD